$698.93
Value $260B
TMO and WST stock compared: price, dividend, valuation and results, from SEC filings.
$698.93
Value $260B
$418.85
Value $30.2B
Thermo Fisher Scientific (TMO) has a market value of $260B and West Pharmaceutical Services (WST) $30.2B. Over the last year, with dividends, TMO moved +21.2% and WST +60.7%. The P/E is 36.7 for TMO and 47.2 for WST. Dividend yield: TMO 0.26%, WST 0.22%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
TMO$260B
WST$30.2B
TMO is 8.6 times WST
Revenue, 12 months
TMO$47.4B
WST$3.4B
TMO is 14 times WST
Net income, 12 months
TMO$7.1B
WST$639M
TMO is 11 times WST
Operating margin
TMO17.9%
WST23.0%
5.1 points apart
ROIC
TMO8.2%
WST19.0%
10.8 points apart
P/E
TMO36.7
WST47.2
WST is 1.3 times TMO
Dividend yield
TMO0.3%
WST0.2%
0.1 points apart
5-year return
TMO+12.1%
WST+0.5%
11.6 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
TMO+12.1%
WST+0.5%
| Period | TMOWith dividends | WSTWith dividends |
|---|---|---|
| 1 year since November 14, 2025 | +21.2%Price +20.8% | +60.7%Price +60.3% |
| 3 years since November 16, 2023 | +49.4%+14.3% a yearPrice +47.9% | +22.7%+7.1% a yearPrice +21.7% |
| 5 years since November 15, 2021 | +12.1%+2.3% a yearPrice +10.5% | +0.5%+0.1% a yearPrice -0.9% |
| 10 years since November 16, 2016 | +380.9%+17.0% a yearPrice +367.5% | +445.6%+18.5% a yearPrice +426.7% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
TMOThermo Fisher ScientificWSTWest Pharmaceutical Services
| Price | $698.93 | $418.85 |
|---|---|---|
| Market value | $260B | $30.2B |
| Enterprise value (EV) | $295B | $29.9B |
| P/E | 36.7 | 47.2 |
| P/E, 5-year median | 32.7 | 44.7 |
| P/B | 4.7 | 10.2 |
| EV/EBIT | 34.8 | 38.3 |
| Free cash flow yield | 2.9% | 1.5% |
| Revenue, 12 months | $47.4B | $3.4B |
|---|---|---|
| Net income, 12 months | $7.1B | $639M |
| Free cash flow, 12 months | $7.6B | $453M |
| Earnings per share, 12 months | $18.96 | $8.91 |
| Revenue growth, year on year | 3.9% | 6.3% |
| Revenue growth a year, past | +6.7%over 5 years | +7.4%over 5 years |
| EPS growth a year, past | +2.1%over 5 years | +8.2%over 5 years |
| Gross margin | – | 37.6% |
|---|---|---|
| Operating margin | 17.9% | 23.0% |
| Net margin | 14.9% | 18.8% |
| ROIC | 8.2% | 19.0% |
| ROE | 13.4% | 21.1% |
| Cash | $6.1B | $464M |
|---|---|---|
| Total debt | $41.4B | $314M |
| Net debt / EBITDA | 3.7 | -0.3 |
| Interest cover | 5.5× | 96.3× |
| Dividend yield | 0.3% | 0.2% |
|---|---|---|
| Dividend per share, 12 months | $1.84 | $0.92 |
| Dividend growth a year, past | +14.3%over 5 years | +5.4%over 5 years |
| Buyback yield | 1.2% | 0.4% |
| Shareholder yield | 1.4% | 0.7% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Thermo Fisher Scientific ($260B) is about 8.6 times West Pharmaceutical Services ($30.2B), at today's prices.
Since November 16, 2016, TMO's price moved +367.5% and WST's +426.7%. With dividends: TMO +380.9% (+17.0% a year), WST +445.6% (+18.5% a year). Past returns do not predict future ones.
The dividend yield at today's price is 0.26% for Thermo Fisher Scientific and 0.22% for West Pharmaceutical Services. Over the last twelve months they paid $1.84 and $0.92 per share.
At today's price, the P/E is 36.7 for TMO and 47.2 for WST. The median of the last five years was 32.7 and 44.7, which shows where each stands against its own past.
Over the last twelve months, the net margin was 14.9% for Thermo Fisher Scientific and 18.8% for West Pharmaceutical Services, and the operating margin 17.9% and 23.0%. Revenue was $47.4B and $3.4B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.